Get started
Author

Robert Małecki

Observed names: Malecki, Robert, Małecki, Robert, R Małecki, R. MALECKI, R. Malecki, R. Małecki, Robert Malecki
Observed institutions: Medical University of Warsaw, Wojskowy Instytut Medycyny Lotniczej, Institute of Cardiology, Międzyleski Szpital Specjalistyczny w Warszawie, Wojskowy Instytut Medyczny, Cardinal Stefan Wyszynski University in Warsaw
ORCID: 0000-0003-3127-6395
Observed ORCID: 0000-0003-3127-6395
OpenAlex ID: A5034840206
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial
2023 · Hiddo J L Heerspink, Jai Radhakrishnan, et al. · The Lancet · 242
PDF
Clinicopathologic correlations of renal pathology in the adult population of Poland
2017 · Agnieszka Perkowska-Ptasinska, Artur Bartczak, et al. · Nephrology Dialysis Transplantation · 57
Safety of intravenous ferric carboxymaltose versus oral iron in patients with nondialysis-dependent CKD: an analysis of the 1-year FIND-CKD trial
2017 · Simon D. Roger, Carlo A. Gaillard, et al. · Nephrology Dialysis Transplantation · 52
PDF
Kidney disease in the elderly: biopsy based data from 14 renal centers in Poland
2016 · Agnieszka Perkowska-Ptasinska, Dominika Deborska-Materkowska, et al. · BMC Nephrology · 44
Optimized Reference Intervals for Plasma Free Metanephrines in Patients With CKD
2018 · Christina Pamporaki, Aleksander Prejbisz, et al. · American Journal of Kidney Diseases · 30
PDF
Effects of Semaglutide With or Without Concomitant Mineralocorticoid Receptor Antagonist Use in Participants With Type 2 Diabetes and Chronic Kidney Disease: A FLOW Trial Prespecified Secondary Analysis
2025 · Peter Rossing, George Bakris, et al. · Diabetes Care · 25
PDF
FRAX prognostic and intervention thresholds in the management of major bone fractures in hemodialysis patients: A two-year prospective multicenter cohort study
2019 · Jerzy Przedlacki, Jolanta Buczyńska-Chyl, et al. · Bone · 22
Atrasentan in patients with IgA nephropathy (ALIGN): final 2·5-year results from a randomised, double-blind, placebo-controlled, phase 3 trial
2026 · Hiddo J L Heerspink, Meg J Jardine, et al. · The Lancet · 15
The standard of urological consultation of patients qualified for renal transplant – a review
2015 · Artur Antoniewicz, Łukasz Zapała, et al. · Editor-in-Chief s Voice List of Authors is an Important Element in a Scientific Publication · 13
PDF
Guideline-Directed Medical Therapy Attainment and Outcomes in Dialysis-Requiring Versus Nondialysis Chronic Kidney Disease in the ISCHEMIA-CKD Trial
2022 · Roy O. Mathew, David J. Maron, et al. · Circulation Cardiovascular Quality and Outcomes · 11
PDF
Optimized procedures for testing plasma metanephrines in patients on hemodialysis
2021 · Christina Pamporaki, Aleksander Prejbisz, et al. · Scientific Reports · 10
PDF
Disturbances of T‐cell interactions with endothelium and the extracellular matrix proteins in a patient with Takayasu arteritis
1994 · J. IMIElA, A. GÓRSKI, et al. · Journal of Internal Medicine · 9
Darbepoetin alfa once monthly corrects anaemia in patients with chronic kidney disease not on dialysis
2014 · Simon D Roger, Elena Kolmakova, et al. · Nephrology · 8
Dietary and Nutritional Strategies to Prevent Uremic Toxin Formation and Slow the Progression of Diabetic Kidney Disease
2025 · Karolina Kędzierska-Kapuza, Anna Grudniewska, et al. · Journal of Clinical Medicine · 5
PDF
Non-Pharmacological Interventions Aimed at Changing the Gut Microbiota for Preventing the Progression of Diabetic Kidney Disease
2025 · Małgorzata Szczuko, Anna Grudniewska, et al. · Nutrients · 3
PDF
Concomitant Sparsentan and Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Patients with IgA Nephropathy (IgAN) in the PROTECT Open-Label Extension (OLE)
2023 · Laura Kooienga, Robert Malecki, et al. · Journal of the American Society of Nephrology · 3
Concomitant Sparsentan (SPAR) and SGLT2 Inhibitors in Patients with IgA Nephropathy in the PROTECT Open-Label Extension (OLE)
2024 · Laura Kooienga, Robert Malecki, et al. · Journal of the American Society of Nephrology · 2
Diabetic kidney disease: Are the reported associations with single-nucleotide polymorphisms disease-specific?
2021 · Marek Saracyn, Bartłomiej Kisiel, et al. · World Journal of Diabetes · 2
PDF
WCN24-752 CONCOMITANT SPARSENTAN AND SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITORS (SGLT2is) IN PATIENTS WITH IMMUNOGLOBULIN A NEPHROPATHY (IgAN) IN THE PROTECT OPEN-LABEL EXTENSION (OLE)
2024 · Radko Komers, Laura Kooienga, et al. · Kidney International Reports · 1
Position paper of the Working Group of three Polish National Consultants in internal medicine, gastroenterology, and cardiology on prevention of gastrointestinal complications during antiplatelet treatment
2009 · Jacek Imiela, Grzegorz Opolski, et al. · Polskie Archiwum Medycyny Wewnętrznej · 1
[Position paper of the Working Group of Three Polish National Consultants in internal medicine, gastroenterology and cardiology concerning the rules of gastrointestinal complications' prevention during antiplatelet treatment].
2009 · Jacek Imiela, Grzegorz Opolski, et al. · PubMed · 1
[Heart failure in advanced age].
2004 · Robert Małecki, Marek Switalski, et al. · PubMed · 1
[Hyperhomocysteinemia as a risk factor for cardiovascular diseases in patients with chronic renal failure].
2000 · R Małecki · PubMed · 1
Guideline-directed medical therapy in Polish patients with chronic coronary syndrome and advanced chronic kidney disease: insights from the ISCHEMIA-CKD trial
2026 · Radosław Pracoń, Rebecca Anthopolos, et al. · Advances in Interventional Cardiology
PDF
Komentarz Nefrologa
2024 · Robert Małecki · Medycyna Faktów
Works count: 46
Citation count: 558
H-index: 10
I10-index: 11
Year
Topic
Type